Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 11, 2012, Pages 1339-1349

  Morgan, Robert J ^a   Alvarez, Ronald D ^b   Armstrong, Deborah K ^c   Burger, Robert A ^d   Castells, Mariana ^e   Chen, Lee May ^f   Copeland, Larry ^g   Crispens, Marta Ann ^h   Gershenson, David ⁱ   Gray, Heidi ^j   Hakam, Ardeshir ^k   Havrilesky, Laura J ^l   Johnston, Carolyn ^m   Lele, Shashikant ⁿ   Martin, Lainie ^d   Matulonis, Ursula A ^e   O'Malley, David M ^g   Penson, Richard T ^o   Remmenga, Steven W ^p   Sabbatini, Paul ^q   Santoso, Joseph T ^r   Schilder, Russell J ^d   Schink, Julian ^s   Teng, Nelson ^t   Werner, Theresa L ^u   Hughes, Miranda ^v   Dwyer, Mary A ^v   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e Da na Farber Brigham and Women s Cancer Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l DUKE CANCER INSTITUTE   (United States)

^m UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

ⁿ ROSWELL PARK CANCER INSTITUTE   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^p NEBRASKA MEDICAL CENTER   (United States)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^s NORTHWESTERN UNIVERSITY   (United States)

^t STANFORD CANCER INSTITUTE   (United States)

^u UNIVERSITY OF UTAH   (United States)

^v National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CYTOREDUCTIVE SURGERY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PELVIS TUMOR; PRACTICE GUIDELINE; REVIEW;

EID: 84871415258     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0140     Document Type: Review

References (62)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) based on November 2011 SEER data submission. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed October 12, 2012.
3. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-2303.
4. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, in press.
5. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-177.
6. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-340.
7. Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012;13:285-291.
8. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-2169.
9. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-445.
10. Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365-374.
11. Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
12. Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121:487-491.
13. Molina R, Escudero JM, Auge JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 2011;32:1087-1095.
14. Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104:863-870.
15. Montagnana M, Danese E, Ruzzenente O, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521-525.
16. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41.
17. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012;124:10-14.
18. Schorge JO, Bradford LS, Del Carmen MG. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future? Clin Adv Hematol Oncol 2011;9:912-918.
19. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873-2883.
20. Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010;119:18-21.
21. Whitney CW, Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia, PA: Gynecologic Oncology Group; 2009.
22. Elattar A, Bryant A, Winter-Roach BA, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011:CD007565.
23. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-953.
24. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol 2011;29:4076-4078.
25. Rauh-Hain JA, Rodriguez N, Growdon WB, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2012;19:959-965.
26. Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology (Williston Park) 2011;25:928-934.
27. Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol 2011;29:4073-4075.
28. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-2497.
29. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-634.
30. Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009;35:135-143.
31. Hoskins PJ. Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking? Curr Opin Oncol 2011;23:501-506.
32. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:26-31.
33. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
34. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-2483.
35. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-2496.
36. Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29:1247-1251.
37. Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol 2011;29:1230-1232.
38. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106.
39. Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res 2011;3:25-38.
40. Griffiths RW, Zee YK, Evans S, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer 2011;21:58-65.
41. Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res 2011;3:219-225.
42. Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-18.
43. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
44. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-2818.
45. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-5171.
46. Tagawa T, Morgan R, Yen Y, Mortimer J. Ovarian cancer: opportunity for targeted therapy. J Oncol 2012;2012:682480.
47. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.
48. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-2045.
49. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract LBA5002.
50. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-1392.
51. Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 5008.
52. Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010;65:1357-1366.
53. Romano A, Torres MJ, Castells M, et al. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127:S67-73.
54. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-580.
55. Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378-382.
56. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373-380.
57. Manivannan V, Decker WW, Stead LG, et al. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:3-5.
58. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609.
59. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-436.
60. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006;103:608-613.
61. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611-4614.
62. Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 2009;101:244-249.